GlassScriptPhysician profile
Carlos A Prendes
NPI 1649381286
$7,052.26
in general payments reported to CMS, 2019-2025
48 companies · $898 in 2025
The $898 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,887 · 2020: $922 · 2021: $1,032 · 2022: $713 · 2023: $946 · 2024: $655 · 2025: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,498.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,323.72 | 2019-2025 | |
| Novo Nordisk INC | $974.37 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $827.40 | 2019-2025 | Airsupra, Farxiga, Xigduo |
| Lilly USA, LLC | $531.81 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $506.05 | 2019-2024 | Prolia, Evenity |
| Pfizer INC. | $274.43 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $259.84 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $252.43 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $196.73 | 2019-2025 | Invega Sustenna, Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $186.81 | 2019-2022 | |
| Glaxosmithkline, LLC. | $186.18 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $155.28 | 2019-2023 | Proquad, Vaxneuvance, Vaxelis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $129.13 | 2019-2025 | Xifaxan |
| Amarin Pharma, INC. | $114.73 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $86.78 | 2019-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Prendes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.